Opportunities in precision oncology and genomic profiling services in Asia Pacific
Launched in 2010 with a $25 million Series A financing led by Third Rock Ventures, Foundation Medicine released its first commercial assay called FoundationOne in 2012. The company develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumours, hematologic malignancies, and sarcomas. In December 2017, the company ’s assay FoundationOne CDx received approval from the US Food and Drug Administration (FDA).
Source: mobihealthnews - Category: Information Technology Source Type: news
More News: Cancer & Oncology | Food and Drug Administration (FDA) | Hematology | Information Technology | Sarcomas